Targeting angiogenesis in cancer: clinical development of bevacizumab (original) (raw)

Nature Clinical Practice Oncology volume 1, pages 39–43 (2004)Cite this article

Abstract

The importance of vascular endothelial growth factor (VEGF) as a regulator of normal and tumor blood vessel growth has been increasingly characterized over the past two decades. VEGF increases vascular permeability and has a well established role in stimulating angiogenesis, a prerequisite of tumor growth. Numerous compounds have been developed to counteract the angiogenic effects of VEGF. One such drug, bevacizumab, a humanized anti-VEGF monoclonal antibody, received FDA approval in the US earlier this year. Results obtained from initial trials showed that this drug was generally well tolerated, and combination studies of bevacizumab and chemotherapeutic agents have been completed in patients with breast, prostate, lung, and colorectal cancers. A randomized trial of bevacizumab used in combination with capecitabine for metastatic breast patients showed no overall improvement of progression-free survival. However, this result contrasted greatly with the data obtained for patients with advanced colorectal cancer, where a combination regimen of bevacizumab, 5-fluorouracil, leucovorin and irinotecan demonstrated a significant improvement in response rates and overall survival compared with chemotherapy alone. This review highlights the key clinical trial data with bevacizumab and discusses the reasons for some of the contrasting results seen in different patient studies.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186
    Article CAS Google Scholar
  2. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795–803
    Article CAS Google Scholar
  3. Ferrara N et al. (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676
    Article CAS Google Scholar
  4. Ferrara N et al. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391–400
    Article CAS Google Scholar
  5. Gordon MS et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850
    Article CAS Google Scholar
  6. Salgaller ML (2003) Technology evaluation: bevacizumab, Genentech/Roche. Curr Opin Mol Ther 5: 657–670
    CAS PubMed Google Scholar
  7. Kerr DJ and La Thangue N. Multitargeted kinase inhibitors: novel trial design. Annals of Oncology, in press
  8. Rugo HS (2004) Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9 (Suppl 1): 43–49
    Article Google Scholar
  9. Kindler L et al. (2003) Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer. Proc Am Soc Clin Oncol 22: 259
    Google Scholar
  10. DeVore R et al. (2000) A randomized phase III trial comparing rhumab VEGF (recombinant humanised monoclonal antibody to VEGF) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV non small cell lung cancer. Proc Am Soc Clin Oncol A1896
  11. Carson WE et al. (2003) A phase II trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma. Proc Am Soc Clin Oncol A705
  12. Willett CG et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145–147
    Article CAS Google Scholar
  13. Miller KD et al. (2002) Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76: S37
  14. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
    Article CAS Google Scholar
  15. Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65
    Article CAS Google Scholar
  16. Hurwitz H et al. (2004) A phase III randomized trial to evaluate the safety and efficacy of adding bevacizumab (rhuMAb VEGF) to bolus IFL in first line metastatic colorectal cancer. N Engl J Med 350: 2335–2342
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Cancer Therapeutics and Clinical Pharmacology,
    David J Kerr
  2. National Translational Cancer Research Network,
    David J Kerr
  3. Clinical Pharmacology Department at the Radcliffe Infirmary, Oxford, UK
    David J Kerr

Authors

  1. David J Kerr
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toDavid J Kerr.

Ethics declarations

Competing interests

The author declared that he has received an educational grant from Roche for an adjuvant trial in stage III colorectal cancer patients. Bevacizumab is used in one study group in the trial, and is co-marketed by Roche.

Rights and permissions

About this article

Cite this article

Kerr, D. Targeting angiogenesis in cancer: clinical development of bevacizumab.Nat Rev Clin Oncol 1, 39–43 (2004). https://doi.org/10.1038/ncponc0026

Download citation